Choosing Between TAS-102 and Regorafenib in Colorectal Cancer

November 30, 2017
Cathy Eng, MD, FACP

Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses choosing between TAS-102 (Lonsurf) and regorafenib (Stivarga) in colorectal cancer.